Posted by Michael Wonder on 10 Sep 2018
NICE turns down Opdivo for adjuvant melanoma therapy
10 September 2018 - BMS drug currently only licensed treatment in this setting.
Bristol-Myers Squibb’s efforts to push the use of Opdivo earlier in the course of melanoma treatment have hit a snag in the UK.
England's cost effectiveness watchdog NICE has decided not to recommend use of the PD-1 inhibitor as an adjuvant treatment for NHS patients with stage III and IV melanoma – in other words to prevent the cancer recurring after surgical resection.
